The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.
Learn about new approvals and the state of the field for each quarter of 2023.
In the first quarter, an mRNA vaccine was approved for COVID-19 prophylaxis in China; Vyznova, a non-genetically modified cell therapy, was approved for corneal dystrophy in Japan; and Hemgenix was approved for hemophilia B in the EU and UK.
In Q2, six new therapies were approved, including two gene therapies that are the first to be approved for their respective indications.
In Q3, an anti-BCMA-targeting CAR T-cell therapy, Fucaso, was approved for multiple myeloma in China and an mRNA vaccine, Daichirona, was approved for COVID-19 in Japan.
In the final quarter of 2023, FDA approved two cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease. Casgevy represents the first-ever approval for a CRISPR-based therapeutic in the United States.
May 7-11, 2024 | Baltimore, MD
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico